Obesity and Metabolic Syndrome - Revision history

Agnivesha at 09:37, 24 February 2024

2024-02-24T09:37:03Z

← Older revision		Revision as of 09:37, 24 February 2024
Line 19:		Line 19:

	\|label3 = Reviewer		\|label3 = Reviewer
	\|data3 = Basisht G.<sup>2</sup>		\|data3 = [[Gopal Basisht\|Basisht G.]]<sup>2</sup>

	\|label4 = Editors		\|label4 = Editors
	\|data4 = Deole Y.S.<sup>2</sup>, Aneesh E.G.<sup>2</sup>, Basisht G. <sup>2</sup>		\|data4 = [[Yogesh Deole\|Deole Y.S.]]<sup>2</sup>, Aneesh E.G.<sup>2</sup>, [[Gopal Basisht\|Basisht G.]]<sup>2</sup>

	\|label5 = Affiliations		\|label5 = Affiliations

Agnivesha at 12:42, 7 March 2023

2023-03-07T12:42:10Z

← Older revision		Revision as of 12:42, 7 March 2023
Line 9:		Line 9:
	\|type=article		\|type=article
	}}		}}


	{{Infobox		{{Infobox
	\|title = Contributors		\|title = Contributors
Line 43:		Line 41:
	\|data9 = 10.47468/CSNE.2021.e01.s09.060		\|data9 = 10.47468/CSNE.2021.e01.s09.060
	}}		}}

	'''Principles of Diagnosis and Management of Metabolic syndrome and Obesity in Ayurveda'''		'''Principles of Diagnosis and Management of Metabolic syndrome and Obesity in Ayurveda'''
			<p style="text-align:justify;">This article is based on lecture delivered by Dr. Mukund Sabnis in Prof.M.S.Baghel Memorial Lecture Series on May 09, 2021.The video lecture can be accessed on the link of [https://fb.watch/8l93wbtQXx/ facebook page.]
	This article is based on lecture delivered by Dr. Mukund Sabnis in Prof.M.S.Baghel Memorial Lecture Series on May 09, 2021.The video lecture can be accessed on the link of [https://fb.watch/8l93wbtQXx/ facebook page.]		<br/>

	<~~div style='text-align:justify;'~~>
	Metabolic syndrome is a group of several cardiovascular risk factors like insulin resistance, obesity, atherogenic dyslipidemia and hypertension. These conditions are interrelated and share underlying mediators, mechanisms and pathways. There has been recent controversy about its definition and its utility. Metabolic syndrome is not an ultimate diagnosis. Metabolic syndrome is a subgroup of patients with shared pathophysiology who are at high risk of developing cardiovascular disease and type 2 diabetes. Pathophysiology and disease pathogenesis can be better understood by observing the clinical features of metabolic syndrome and their interrelation.		Metabolic syndrome is a group of several cardiovascular risk factors like insulin resistance, obesity, atherogenic dyslipidemia and hypertension. These conditions are interrelated and share underlying mediators, mechanisms and pathways. There has been recent controversy about its definition and its utility. Metabolic syndrome is not an ultimate diagnosis. Metabolic syndrome is a subgroup of patients with shared pathophysiology who are at high risk of developing cardiovascular disease and type 2 diabetes. Pathophysiology and disease pathogenesis can be better understood by observing the clinical features of metabolic syndrome and their interrelation.
			<br/>
	[[Ayurveda]] has a vast scope in the management of metabolic syndrome. Clubbing of modern medicine concepts with Ayurveda is essential for this. The pathophysiology of metabolic syndrome shall be clubbed with disorders due to overnutrition (santarpanajanya vyadhi) in [[Ayurveda]]. [Cha.Sa. [[Sutra Sthana]] 23/3-5]		[[Ayurveda]] has a vast scope in the management of metabolic syndrome. Clubbing of modern medicine concepts with Ayurveda is essential for this. The pathophysiology of metabolic syndrome shall be clubbed with disorders due to overnutrition (santarpanajanya vyadhi) in [[Ayurveda]]. [Cha.Sa. [[Sutra Sthana]] 23/3-5] </p>

	==Definition==		==Definition==

Agnivesha at 04:48, 21 September 2022

2022-09-21T04:48:33Z

← Older revision		Revision as of 04:48, 21 September 2022
Line 1:		Line 1:
			{{CiteButton}}
	{{#seo:		{{#seo:
	\|title=Obesity and Metabolic Syndrome		\|title=Obesity and Metabolic Syndrome

Eganeesh at 10:39, 15 June 2022

2022-06-15T10:39:52Z

← Older revision		Revision as of 10:39, 15 June 2022
Line 33:		Line 33:
	\|data6 = jeevanrekha1996@rediffmail.com, carakasamhita@gmail.com		\|data6 = jeevanrekha1996@rediffmail.com, carakasamhita@gmail.com

	\|label7 = ~~Date of first publication:~~		\|label7 = Publisher
	\|data7 = ~~June 09~~, ~~2021~~		\|data7 = [[Charak Samhita Research, Training and Development Centre]], I.T.R.A., Jamnagar, India

	\|label8 = DOI		\|label8 = Date of first publication:
	\|~~data8~~ = 10.47468/CSNE.2021.e01.s09.060		\|data8 = June 09, 2021

			\|label9 = DOI
			\|data9 = 10.47468/CSNE.2021.e01.s09.060
	}}		}}

Agnivesha at 06:38, 25 January 2022

2022-01-25T06:38:08Z

← Older revision		Revision as of 06:38, 25 January 2022
Line 31:		Line 31:

	\|label6 = Correspondence email:		\|label6 = Correspondence email:
	\|data6 = carakasamhita@gmail.com		\|data6 = jeevanrekha1996@rediffmail.com, carakasamhita@gmail.com

	\|label7 = Date of first publication:		\|label7 = Date of first publication:
Line 37:		Line 37:

	\|label8 = DOI		\|label8 = DOI
	\|data8 = ~~Under process~~		\|data8 = 10.47468/CSNE.2021.e01.s09.060
	}}		}}

Agnivesha at 07:44, 30 September 2021

2021-09-30T07:44:12Z

← Older revision		Revision as of 07:44, 30 September 2021
Line 42:		Line 42:
	'''Principles of Diagnosis and Management of Metabolic syndrome and Obesity in Ayurveda'''		'''Principles of Diagnosis and Management of Metabolic syndrome and Obesity in Ayurveda'''

	This article is based on lecture delivered by Dr. Mukund Sabnis in Prof.M.S.Baghel Memorial Lecture Series on May 09, 2021.		This article is based on lecture delivered by Dr. Mukund Sabnis in Prof.M.S.Baghel Memorial Lecture Series on May 09, 2021.The video lecture can be accessed on the link of [https://fb.watch/8l93wbtQXx/ facebook page.]

	<div style='text-align:justify;'>		<div style='text-align:justify;'>
Line 298:		Line 298:

	[[Ashtauninditiya Adhyaya]], [[Santarpaniya Adhyaya]], [[Prameha Nidana Adhyaya]], [[Prameha Chikitsa Adhyaya]]		[[Ashtauninditiya Adhyaya]], [[Santarpaniya Adhyaya]], [[Prameha Nidana Adhyaya]], [[Prameha Chikitsa Adhyaya]]


			<big>'''Link to video lecture: https://fb.watch/8l93wbtQXx/'''</big>

	<big>'''[[Special:ContactMe\|Send us your suggestions and feedback on this page.]]'''</big>		<big>'''[[Special:ContactMe\|Send us your suggestions and feedback on this page.]]'''</big>

Eganeesh: /* Related Chapters */

2021-09-24T00:30:21Z

Related Chapters

← Older revision		Revision as of 00:30, 24 September 2021
Line 298:		Line 298:

	[[Ashtauninditiya Adhyaya]], [[Santarpaniya Adhyaya]], [[Prameha Nidana Adhyaya]], [[Prameha Chikitsa Adhyaya]]		[[Ashtauninditiya Adhyaya]], [[Santarpaniya Adhyaya]], [[Prameha Nidana Adhyaya]], [[Prameha Chikitsa Adhyaya]]

			<big>'''[[Special:ContactMe\|Send us your suggestions and feedback on this page.]]'''</big>

	== Reference Source==		== Reference Source==

Agnivesha: /* Dietary management */

2021-06-09T07:58:55Z

Dietary management

← Older revision		Revision as of 07:58, 9 June 2021
Line 269:		Line 269:
	In fatty liver, in the first stage, insulin resistance is observed at the hepatocytes. There is a reduction in fatty oxidation; increase in fatty acid influx into liver; increased lipogenesis and increased triglycerides. The second stage is lipid peroxidation. So the management should target lipid peroxidation, TNF-alpha, cytokine cascade, reducing the liquid/slimy content (kleda), correcting the metabolism ([[agni]]) etc.		In fatty liver, in the first stage, insulin resistance is observed at the hepatocytes. There is a reduction in fatty oxidation; increase in fatty acid influx into liver; increased lipogenesis and increased triglycerides. The second stage is lipid peroxidation. So the management should target lipid peroxidation, TNF-alpha, cytokine cascade, reducing the liquid/slimy content (kleda), correcting the metabolism ([[agni]]) etc.

	Ayurvedic interventions considerably control the hormones - adiponectin and leptin secreted by adipose tissue. The treatment creates insulin sensitivity and reduces inflammation at adipocyte level. Adiponectin is inversely proportional to obesity. If weight is more, adiponectin level is less and vice versa. However, in people having optimum [[meda]] (meda sara), adiponectin level increases with weight.		Ayurvedic interventions considerably control the hormones - adiponectin and leptin secreted by adipose tissue. The treatment creates insulin sensitivity and reduces inflammation at adipocyte level. Adiponectin is inversely proportional to obesity. If weight is more, adiponectin level is less and vice versa. However, in people having optimum [[meda dhatu]] (meda sara), adiponectin level increases with weight.

	=== Effect of therapeutic enema ( [[basti]]) as a treatment in obesity===		=== Effect of therapeutic enema ( [[basti]]) as a treatment in obesity===

Agnivesha: /* Interactions */

2021-06-09T07:58:28Z

Interactions

← Older revision		Revision as of 07:58, 9 June 2021
Line 293:		Line 293:

	'''A:''' Bhutagni works like a vehicle. Bhutagni carries the fuel (food) to the tissues ([[dhatu]]). The fuel is filled in a vehicle (body gut) only when it is empty (hungry state). If we overfill the tank (gut) beyond its capacity, it leads to engine dysfunction (agni vaishamya). Likewise, when there is excess body fluid (kleda) formation, aap bhutagni becomes less. In this condition, the diet control and medicines advised should work on aap mahabhutaagni. The water intake must be restricted. The astringent medicines should be given as they have kledashoshana (drying) and [[stambhana]] (obstructing) property.		'''A:''' Bhutagni works like a vehicle. Bhutagni carries the fuel (food) to the tissues ([[dhatu]]). The fuel is filled in a vehicle (body gut) only when it is empty (hungry state). If we overfill the tank (gut) beyond its capacity, it leads to engine dysfunction (agni vaishamya). Likewise, when there is excess body fluid (kleda) formation, aap bhutagni becomes less. In this condition, the diet control and medicines advised should work on aap mahabhutaagni. The water intake must be restricted. The astringent medicines should be given as they have kledashoshana (drying) and [[stambhana]] (obstructing) property.
			</div>

	~~</div>~~		== Related Chapters ==

			[[Ashtauninditiya Adhyaya]], [[Santarpaniya Adhyaya]], [[Prameha Nidana Adhyaya]], [[Prameha Chikitsa Adhyaya]]

			== Reference Source==
	<div id="BackToTop" class="noprint" style="background-color:#DDEFDD; position:fixed;		<div id="BackToTop" class="noprint" style="background-color:#DDEFDD; position:fixed;
	bottom:32px; left:2%; z-index:9999; padding:0; margin:0;"><span style="color:blue;		bottom:32px; left:2%; z-index:9999; padding:0; margin:0;"><span style="color:blue;

Agnivesha: /* Selection of biomarker */

2021-06-09T07:55:58Z

Selection of biomarker

← Older revision		Revision as of 07:55, 9 June 2021
Line 89:		Line 89:
	In most of the researches in obesity, weight is considered as the main parameter. However, it is a very superficial parameter. Weight reduction to make the obese person thin is a primary goal in general practice. However, the most crucial concern in treating an obese person is not to make the person thin but to transform an unhealthy obese person to a healthy obese person. [Su.Sa. Sutra Sthana 35/34] If the person has adipose tissue with optimum quality (meda sara), it is challenging to reduce weight. Similarly, in hyperhomocysteinemia, one should see whether the patient is with optimal quality of blood tissue (rakta sara), before treating the person. So while treating obesity and metabolic syndrome through [[Ayurveda]], the targets should be different, and the biomarkers should be more specific.		In most of the researches in obesity, weight is considered as the main parameter. However, it is a very superficial parameter. Weight reduction to make the obese person thin is a primary goal in general practice. However, the most crucial concern in treating an obese person is not to make the person thin but to transform an unhealthy obese person to a healthy obese person. [Su.Sa. Sutra Sthana 35/34] If the person has adipose tissue with optimum quality (meda sara), it is challenging to reduce weight. Similarly, in hyperhomocysteinemia, one should see whether the patient is with optimal quality of blood tissue (rakta sara), before treating the person. So while treating obesity and metabolic syndrome through [[Ayurveda]], the targets should be different, and the biomarkers should be more specific.

	==Selection of biomarker==		===Selection of biomarker===

	The selection of biomarker depends on the type of disorder and drug used for therapy. The correct selection of biomarker sheds light on the mode of action of that particular drug. The medicines described for the treatment of obesity vary in their mode of action. The different medicines for reducing body tissues (lekhana) act differently. Some medicines work on fatty liver; some on skeletal muscles; some have insulin sensitizing action; and some have anti oxidant activities specific to the adipose tissue ([[meda dhatu]]). So depending on the underlying pathology and drug, the biomarker should be selected. If we suspect inflammatory involvement, then the best biomarker is either Adiponectin or high sensitive c reactive protein (HSCRP). Adiponectin level suggests the presence of inflammation, tendency of atherogenesis, or presence of insulin resistance at the cellular level. In different types of metabolic disorders like hypercholesterolemia, hyperhomocysteinemia etc. the specific biomarker should be selected.		The selection of biomarker depends on the type of disorder and drug used for therapy. The correct selection of biomarker sheds light on the mode of action of that particular drug. The medicines described for the treatment of obesity vary in their mode of action. The different medicines for reducing body tissues (lekhana) act differently. Some medicines work on fatty liver; some on skeletal muscles; some have insulin sensitizing action; and some have anti oxidant activities specific to the adipose tissue ([[meda dhatu]]). So depending on the underlying pathology and drug, the biomarker should be selected. If we suspect inflammatory involvement, then the best biomarker is either Adiponectin or high sensitive c reactive protein (HSCRP). Adiponectin level suggests the presence of inflammation, tendency of atherogenesis, or presence of insulin resistance at the cellular level. In different types of metabolic disorders like hypercholesterolemia, hyperhomocysteinemia etc. the specific biomarker should be selected.